Evaluation of Efficacy and Tolerability of Hizentra®
Unknown status
University of South Florida
N/A
2010-10-01
The purpose of this study is to measure the changes in the Treatment Satisfaction
Questionnaire for Medication in the areas of effectiveness, side effects, and convenience of
administration of each medication in Primary Immunodeficiency Disorder (PIDD) subjects
transitioning from subcutaneous Vivaglobin® to Hizentra®.
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
Terminated
CSL Behring
Phase 1
2011-10-01
The study is being done with patients with Myasthenia Gravis (MG), age 18-80 years, positive
acetylcholine receptor antibody, receiving greater than 30mg of prednisone daily. Patients
may or may not be receiving anticholinesterase agents. A common treatment for patients with
this disease includes the administration of intravenous immunoglobulin (IVIG), which is a
plasma protein that is given to help maintain adequate antibody levels to prevent infections
and decrease the symptoms of the disease of Myasthenia Gravis. This study is being done to
test if giving this medication in a subcutaneous form (into the fat of the abdomen, legs and
thighs) will be better tolerated for patients with Myasthenia Gravis.
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
Terminated
St. Louis University
Phase 1
2011-10-01
The study is being done with patients with Myasthenia Gravis (MG), age 18-80 years, positive
acetylcholine receptor antibody, receiving greater than 30mg of prednisone daily. Patients
may or may not be receiving anticholinesterase agents. A common treatment for patients with
this disease includes the administration of intravenous immunoglobulin (IVIG), which is a
plasma protein that is given to help maintain adequate antibody levels to prevent infections
and decrease the symptoms of the disease of Myasthenia Gravis. This study is being done to
test if giving this medication in a subcutaneous form (into the fat of the abdomen, legs and
thighs) will be better tolerated for patients with Myasthenia Gravis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
